Antibody markers in the diagnosis of inflammatory bowel disease

World Journal of Gastroenterology

Volumn 22, Issue 3, 2016, Pages 1304-1310

  Mitsuyama, Keiichi ^a   Niwa, Mikio ^b   Takedatsu, Hidetoshi ^a   Yamasaki, Hiroshi ^a   Kuwaki, Kotaro ^a   Yoshioka, Shinichiro ^a   Yamauchi, Ryosuke ^a   Fukunaga, Shuhei ^a   Torimura, Takuji ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Base Technology Center   (Japan)

Author keywords

Biomarker; Crohn's disease; Serological antibody; Ulcerative colitis

Indexed keywords

ANTI CAENORHABDITIS ELEGANS ANTIBODY; ANTI COCKTAIL MULTIPLE ANTIGENIC PEPTIDE ANTIBODY; ANTI FLAGELLIN ANTIBODY; ANTI I2 ANTIBODY; ANTI MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS ANTIBODY; ANTI OUTER MEMBRANE PORIN C ANTIBODY; ANTI SACCHAROMYCES CEREVISIAE ANTIBODY; ANTI TCP ANTIBODY; ANTIBODY; AUTOANTIBODY; MICROBIAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PANCREATIC ANTIBODY; PEPTIDE ANTIBODY; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; BIOLOGICAL MARKER;

CLINICAL FEATURE; DISEASE CLASSIFICATION; HUMAN; INFLAMMATORY BOWEL DISEASE; PHENOTYPE; PROGNOSIS; RADIODIAGNOSIS; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; BLOOD; COLITIS, ULCERATIVE; CROHN DISEASE; IMMUNOLOGY; MICROBIOLOGY; PREDICTIVE VALUE; SEROLOGY;

ANTIBODIES; ANTIBODIES, BACTERIAL; AUTOANTIBODIES; BIOMARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEROLOGIC TESTS;

EID: 84961344605     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i3.1304     Document Type: Review

References (45)

1. Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42: 788-791 [PMID: 9691915 DOI: 10.1136/gut.42.6.788]
2. Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, Tekkis PP. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006; 101: 2410-2422 [PMID: 16952282 DOI: 10.1111/ j.1572-0241.2006.00840.x]
3. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115: 822-829 [PMID: 9753483 DOI: 10.1016/S0016-5085(98)70252-5]
4. Gionchetti P, Vecchi M, Rizzello F, Ferretti M, Calabresi C, Venturi A, Bianchi MB, Brignola C, Sinico RA, De Franchis R, Miglioli M, Campieri M. Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils. Gut 1997; 40: 102-104 [PMID: 9155584 DOI: 10.1136/gut.40.1.102]
5. Lakatos PL, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Barta Z, Stocker W, Papp J, Veres G, Papp M. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis 2009; 15: 365-374 [PMID: 18972554 DOI: 10.1002/ibd.20778]
6. Desplat-Jégo S, Johanet C, Escande A, Goetz J, Fabien N, Olsson N, Ballot E, Sarles J, Baudon JJ, Grimaud JC, Veyrac M, Chamouard P, Humbel RL. Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol 2007; 13: 2312-2318 [PMID: 17511029 DOI: 10.3748/wjg.v13. i16.2312]
7. Lawrance IC, Hall A, Leong R, Pearce C, Murray K. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm Bowel Dis 2005; 11: 890-897 [PMID: 16189418 DOI: 10.1097/01.MIB.0000182872.76434.8c]
8. Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, Parratt D. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988; 297: 1105-1106 [PMID: 3143445 DOI: 10.1136/bmj.297.6656.1105]
9. Hisabe T, Matsui T, Sakurai T, Murakami Y, Tanabe H, Matake H, Yao T, Kamachi S, Iwashita A. Anti-Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value. J Gastroenterol 2003; 38: 121-126 [PMID: 12640524 DOI: 10.1007/s005350300020]
10. Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, Weishauss O, Spector L, Shtevi A, Altstock RT, Dotan N, Halpern Z. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006; 131: 366-378 [PMID: 16890590 DOI: 10.1053/j.gastro.2006.04.030]
11. Seow CH, Stempak JM, Xu W, Lan H, Griffiths AM, Greenberg GR, Steinhart AH, Dotan N, Silverberg MS. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol 2009; 104: 1426-1434 [PMID: 19491856 DOI: 10.1038/ajg.2009.79]
12. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR. Selected loss of tolerance evidenced by Crohn' s disease-associated immune responses to auto-and microbial antigens. Gastroenterology 2002; 123: 689-699 [PMID: 12198693 DOI: 10.1053/gast.2002.35379]
13. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004; 99: 2235-2241 [PMID: 15555007 DOI: 10.1111/j.1572-0241.2004.40369.x]
14. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56: 1394-1403 [PMID: 17456509 DOI: 10.1136/ gut.2006.108043]
15. Joossens S, Colombel JF, Landers C, Poulain D, Geboes K, Bossuyt X, Targan S, Rutgeerts P, Reinisch W. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut 2006; 55: 1667-1669 [PMID: 16687433 DOI: 10.1136/gut.2005.089623]
16. Hui T, Landers C, Vasiliauskas E, Abreu M, Dubinsky M, Papadakis KA, Price J, Lin YC, Huiying Y, Targan S, Fleshner P. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum 2005; 48: 1254-1262 [PMID: 15868228 DOI: 10.1007/s10350-005-0013-0]
17. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004; 113: 1296-1306 [PMID: 15124021 DOI: 10.1172/JCI20295]
18. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128: 2020-2028 [PMID: 15940634 DOI: 10.1053/j.gastro.2005.03.046]
19. Sitaraman SV, Klapproth JM, Moore DA, Landers C, Targan S, Williams IR, Gewirtz AT. Elevated flagellin-specific immunoglobulins in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 2005; 288: G403-G406 [PMID: 15388489 DOI: 10.1152/ajpgi.00357.2004]
20. Chiodini RJ, Van Kruiningen HJ, Merkal RS, Thayer WR, Coutu JA. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease. J Clin Microbiol 1984; 20: 966-971 [PMID: 6511878]
21. Naser S, Shafran I, El-Zaatari F. Mycobacterium avium subsp. paratuberculosis in Crohn's disease is serologically positive. Clin Diagn Lab Immunol 1999; 6: 282 [PMID: 10189224]
22. Nakase H, Nishio A, Tamaki H, Matsuura M, Asada M, Chiba T, Okazaki K. Specific antibodies against recombinant protein of insertion element 900 of Mycobacterium avium subspecies paratuberculosis in Japanese patients with Crohn's disease. Inflamm Bowel Dis 2006; 12: 62-69 [PMID: 16374261 DOI: 10.1097/01. MIB.0000191671.12229.47]
23. Oshitani N, Hato F, Kitagawa S, Maeda K, Higuchi K, Matsumoto T, Arakawa T. Analysis of intestinal HLA-DR bound peptides and dysregulated immune responses to enteric flora in the pathogenesis of inflammatory bowel disease. Int J Mol Med 2003; 11: 99-104 [PMID: 12469227 DOI: 10.3892/ijmm.11.1.99]
24. Oshitani N, Hato F, Kitagawa S, Watanabe K, Fujiwara Y, Higuchi K, Matsumoto T, Arakawa T. Distinct elevation of levels of anti-Caenorhabditis elegans antibody in sera of patients with inflammatory bowel disease. Clin Diagn Lab Immunol 2003; 10: 856-861 [PMID: 12965916 DOI: 10.1128/cdli.10.5.856-861.2003]
25. Saito H, Fukuda Y, Katsuragi K, Tanaka M, Satomi M, Shimoyama T, Saito T, Tachikawa T. Isolation of peptides useful for differential diagnosis of Crohn's disease and ulcerative colitis. Gut 2003; 52: 535-540 [PMID: 12631665 DOI: 10.1136/gut.52.4.535]
26. Mitsuyama K, Niwa M, Masuda J, Kuwaki K, Yamasaki H, Takedatsu H, Kobayashi T, Sata M. Isolation and characterization of a novel short peptide associated with Crohn's disease. Clin Exp Immunol 2011; 166: 72-79 [PMID: 21797848 DOI: 10.1111/ j.1365-2249.2011.04444.x]
27. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96: 730-734 [PMID: 11280542 DOI: 10.1111/j.1572-0241.2001.03613.x]
28. Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P, Oberhuber G, Vogelsang H, Rutgeerts P, Colombel JF. The value of serologic markers in indeterminate colitis: A prospective follow-up study. Gastroenterology 2002; 122: 1242-1247 [PMID: 11984510 DOI: 10.1053/gast.2002.32980]
29. Yu CS, Pemberton JH, Larson D. Ileal pouch-anal anastomosis in patients with indeterminate colitis: long-term results. Dis Colon Rectum 2000; 43: 1487-1496 [PMID: 11089581 DOI: 10.1007/ BF02236726]
30. Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005; 54: 1232-1236 [PMID: 16099791 DOI: 10.1136/ gut.2004.060228]
31. Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut 2000; 46: 58-63 [PMID: 10601056 DOI: 10.1136/ gut.46.1.58]
32. Halfvarson J, Standaert-Vitse A, Järnerot G, Sendid B, Jouault T, Bodin L, Duhamel A, Colombel JF, Tysk C, Poulain D. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut 2005; 54: 1237-1243 [PMID: 15863472 DOI: 10.1136/gut.2005.066860]
33. Mei L, Targan SR, Landers CJ, Dutridge D, Ippoliti A, Vasiliauskas EA, Papadakis KA, Fleshner PR, Rotter JI, Yang H. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology 2006; 130: 1078-1085 [PMID: 16618402 DOI: 10.1053/j.gastro.2006.02.013]
34. Török HP, Glas J, Hollay HC, Gruber R, Osthoff M, Tonenchi L, Brückl C, Mussack T, Folwaczny M, Folwaczny C. Serum antibodies in first-degree relatives of patients with IBD: A marker of disease susceptibility? A follow-up pilot-study after 7 years. Digestion 2005; 72: 119-123 [PMID: 16172548 DOI: 10.1159/000088366]
35. Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004; 53: 1117-1122 [PMID: 15247177 DOI: 10.1136/gut.2003.030734]
36. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126: 414-424 [PMID: 14762777 DOI: 10.1053/j.gastro.2003.11.015]
37. Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang H. Serum immune responses predict rapid disease progression among children with Crohn' s disease: immune responses predict disease progression. Am J Gastroenterol 2006; 101: 360-367 [PMID: 16454844 DOI: 10.1111/j.1572-0241.2006.00456.x]
38. Kuisma J, Järvinen H, Kahri A, Färkkilä M. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand J Gastroenterol 2004; 39: 544-548 [PMID: 15223678 DOI: 10.1080/00365520410004668]
39. Gupta N, Cohen SA, Bostrom AG, Kirschner BS, Baldassano RN, Winter HS, Ferry GD, Smith T, Abramson O, Gold BD, Heyman MB. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology 2006; 130: 1069-1077 [PMID: 16618401 DOI: 10.1053/j.gastro.2006.02.003]
40. Vecchi M, Spina L, Cavallaro F, Pastorelli L. Do antibodies have a role in IBD pathogenesis? Inflamm Bowel Dis 2008; 14 Suppl 2: S95-S96 [PMID: 18816674 DOI: 10.1002/ibd.20699]
41. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001; 120: 1347-1355 [PMID: 11313304 DOI: 10.1053/gast.2001.23966]
42. Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 1458-1462 [PMID: 12094865 DOI: 10.1111/j.1572-0241.2002.05689.x]
43. Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK, Rutgeerts P. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13: 123-128 [PMID: 17206703 DOI: 10.1002/ibd.20054]
44. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996; 71: 431-436 [PMID: 8628021 DOI: 10.1016/S0025-6196(11)64083-4]
45. Dotan I. Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification. Expert Rev Gastroenterol Hepatol 2007; 1: 265-274 [PMID: 19072419 DOI: 10.1586/17474124.1.2.265]